Core Insights - The core viewpoint of the article highlights the significant financial performance of Servier Group for the fiscal year 2024-2025, achieving a consolidated revenue of €6.9 billion, representing a 16.2% increase compared to the previous fiscal year [1][2]. Financial Performance - The revenue growth was primarily driven by a 16.9% increase in sales volume, contributing an additional €1 billion, while currency fluctuations negatively impacted revenue by 2.0%, approximately €118 million [3]. - The EBITDA for the fiscal year reached €1.9 billion, with an EBITDA margin of 28.2%, up from 22.2% in the previous year, attributed to strong sales growth in oncology and effective cost control [3][4]. - The group exceeded its revenue target of €6 billion, showcasing robust growth momentum and the ability to provide more treatment options for patients [1]. Oncology Sector Growth - The oncology segment achieved remarkable progress, with sales revenue reaching €2.21 billion, a 54.6% increase, driven by the launch of Voranigo® in the U.S. market [4][6]. - The oncology business now accounts for 32.2% of total revenue, up from 24.2% in the previous fiscal year [4]. - The U.S. subsidiary's revenue grew by 70.3% to €1.496 billion, contributing 21.8% to the group's total revenue [5]. Research and Development Strategy - Servier's innovation strategy focuses on both organic growth and external expansion, integrating artificial intelligence and data technology into the drug development process [8][11]. - The group has established a strong R&D pipeline targeting rare neurological diseases, with a focus on mRNA small molecules and monoclonal antibodies [8][9]. - The company has signed multiple collaboration agreements to enhance its oncology pipeline, including partnerships for targeted therapies and acquisitions to strengthen its position in acute leukemia [7][11]. Cardiovascular and Metabolic Business - The cardiovascular and metabolic segment accounted for 43.3% of total revenue, driven by strong sales of the product Aipai Long® and single-pill combinations [10]. - The company is addressing patient adherence issues by submitting applications for innovative hypertension therapies [10]. Commitment to Patient Needs - Servier aims to integrate patient perspectives into every stage of the drug lifecycle, emphasizing its commitment to addressing unmet medical needs in oncology and neurology [12].

格隆汇1月28日｜施维雅集团公布2024-2025财年业绩，集团于期内实现收入69亿欧元，同比增长 16.2%，超额完成60亿欧元的年度目标。其中，肿瘤业务成为核心增长引擎，实现销售收入22.1亿欧 元，同比增长54.6%，占总收入比重提升至32.2%。增长主要得益于罕见脑部肿瘤靶向药Voranigo®在美 国上市后带动肿瘤药物销量提升。另外，心血管代谢领域表现稳健，贡献集团总收入的43.3%，核心产 品静脉疾病治疗药爱脉朗®销售业绩强劲。 ...